2013 Fiscal Year Final Research Report
Study on development and clinical application of the innovative isolated pancreas perfusion therapy for the refractory pancreatic cancer
| Project/Area Number |
23390306
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
MURATA Satoru 日本医科大学, 医学部, 准教授 (80322501)
|
|---|
| Project Period (FY) |
2011-04-01 – 2014-03-31
|
| Keywords | 膵 / 灌流療法 / 経皮的 / 急性期障害 / 亜急性期障害 / 病理学的変化 / 臨床試験 |
|---|
| Research Abstract |
The aim of this study was to evaluate the feasibility of percutaneous isolated pancreas perfusion (PIPP). (1) Animal study: PIPP was performed at 4 infusion rates. The organs were examined angiographically and histopathologically, and the maximum platinum concentration (Cmax) and the concentration–time curve (AUC) were measured. (2) Clinical study: We have begun the 3 + 3 cisplatin (from 20 mg/m2) dose-escalation design was selected to determine the dose-limiting adverse events toxicity (DLT) and maximum tolerated dose for advanced pancreas cancer. (1) Angiography confirmed the PIPP system. Histopathological examinations showed no abnormalities in the pancreas only at an infusion rate of 40 ml/min. The pancreas to systemic exposure ratio was over 70-fold in terms of Cmax and 58-fold in terms of AUC. (2) PIPP was successfully performed in 5 patients. No DLTs were observed until 25 mg/m2 of cisplatin. In conclusion, PIPP appears a safe and feasible technique for pancreas cancer.
|
Research Products
(34 results)
